One-hour post-load plasma glucose level predicts future type 2 diabetes in a community-based study of Hong Kong Chinese workforce.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE
    • Publication Information:
      Publication: 1993- : Limerick : Elsevier Scientific Publishers
      Original Publication: Amsterdam : Elsevier Science Publishers B.V., c1985-
    • Subject Terms:
      Diabetes Mellitus, Type 2*/blood ; Diabetes Mellitus, Type 2*/epidemiology ; Diabetes Mellitus, Type 2*/diagnosis ; Blood Glucose*/analysis ; Blood Glucose*/metabolism ; Glucose Tolerance Test*; Humans ; Hong Kong/epidemiology ; Male ; Adult ; Female ; Middle Aged ; Glucose Intolerance/blood ; Glucose Intolerance/epidemiology ; Glucose Intolerance/diagnosis ; Young Adult ; Adolescent ; Fasting/blood ; Asian People/statistics & numerical data ; Disease Progression ; East Asian People
    • Abstract:
      Background: We compared performance of high 1-hour PG level, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) in predicting type 2 diabetes in a longitudinal community-based cohort of Hong Kong Chinese.
      Methods: Between 2001 and 2003, 472 adults aged 18-55 years without diabetes underwent 75-gram oral glucose tolerance test (OGTT). Between 2012 and 2014, progression to diabetes was ascertained by reviewing medical records or repeating OGTT and HbA 1c . We defined high 1-hour PG as PG ≥ 8.6 mmol/L at 1-hour.
      Results: In this cohort, 23.5% had normal glucose tolerance and high 1-hour PG, 10.0% had isolated IGT, 4.2% had isolated IFG. Over 12-year follow-up, 9.3% developed type 2 diabetes. In logistic regression, high 1-hour PG was associated with progression to type 2 diabetes with adjusted odds ratio (95% CI) of 4.20 (1.60, 12.40), independent of IFG, IGT and other clinical variables. Areas under ROC (95% CI) for type 2 diabetes were similar between 1-hour (0.84 [0.78, 0.89], 2-hour (0.79 [0.72, 0.86]) and fasting PG (0.79 [0.71, 0.86]).
      Conclusion: High 1-hour PG identified young Chinese with 5-fold increased risk of type 2 diabetes independent of other intermediate hyperglycaemia status and clinical factors. 1-hour PG is similar to fasting and 2-hour PG in predicting type 2 diabetes.
      Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.O.Y.L. has served as a member of advisory panel for Amgen, AstraZeneca, Boehringer Ingelheim and Sanofi and received research support from Amgen, Asia Diabetes Foundation, Bayer, Biogen, Boehringer Ingelheim, Lee’s Pharmaceutical, MSD, Novo Nordisk, Roche, Sanofi, Sugardown Ltd, Takeda, outside the submitted work. J.C.N.C. has received institutional grants and/or consultancy fees from Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Celltrion, Hua Medicine, Lee Powder, Lilly, Merck, MSD, Novartis, Pfizer, Sanofi, Servier, Viatris Pharmaceuticals and Zuelig Pharma; acts as CEO (probono) in Asia Diabetes Foundation and is a founding director of GemVCare, outside the submitted work. In addition, J.C.N.C. holds patents of using biogenetic markers for precision prevention and treatment of diabetes and its complications. A.P.S.K. has received research grants and/or speaker honoraria from Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli-Lilly, Kyowa Kirin, Merck Serono, Novo Nordisk, Pfizer and Sanofi, outside the submitted work. R.C.W.M. has received grants from AstraZeneca, Bayer, Pfizer, Novo Nordisk, Sanofi, Tricida Inc., speaker honorarium from AstraZeneca, Bayer and Boehringer Ingelheim, and has received support from the Hong Kong Government Innovation and Technology Commission and its Technology Start-up Support Scheme for Universities (TSSSU), as co-founder of a technology start-up GemVCare which provides genetic testing for diabetes and diabetes complications, outside the submitted work.
      (Copyright © 2024 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: 1-hour plasma glucose; Chinese; Impaired fasting glucose; Impaired glucose tolerance; Intermediate hyperglycaemia
    • Accession Number:
      0 (Blood Glucose)
    • Publication Date:
      Date Created: 20240525 Date Completed: 20240609 Latest Revision: 20240815
    • Publication Date:
      20240816
    • Accession Number:
      10.1016/j.diabres.2024.111718
    • Accession Number:
      38796080